Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Crinetics Pharmaceuticals, Inc.

< Previous 1 2 Next >
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.